Erdosteine
R05C - Expectorants, excl. combinations with cough suppressants
ATC R05CB15
Small molecule
Natural product
JFDA label: Mucotec 150 Capsules
Mechanism of Action
— Expectorant; — Anti-inflammatory, anti-oxidant
Indications
Off-label
- Bronchitis, Chronic
- Pulmonary Disease, Chronic Obstructive
Pregnancy & Lactation
Pregnancy
Chemistry & Properties
| Formula | C8H11NO4S2 |
|---|---|
| Molecular weight | 249.31 g/mol |
| IUPAC name | 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid |
| CAS | 84611-23-4 |
| PubChem CID | 65632 |
| InChIKey | QGFORSXNKQLDNO-UHFFFAOYSA-N |
| logP | -0.05 (XLogP -0.1) |
| Polar surface area | 83.47 Ų |
| H-bond acceptors / donors | 5 / 2 |
| Drug-likeness (QED) | 0.71 |
| Lipinski violations | 0 |
SMILES
O=C(O)CSCC(=O)NC1CCSC1=OBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 10.0% |
|---|---|
| Half-life | 1.35 h |
| Volume of distribution | 0.193 L/kg |
| Protein binding | 55.6% |
| BBB penetrant | No |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2C19 | Substrate | — |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (3)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Mucotec 150 Capsules | Capsule 150 mg | 20 cap | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.100 |
| Mucotec 300 Capsules | Capsule 300 mg | 10 cap | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.100 |
| Mucotec Suspension | Suspension 35 mg/ml | 60 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.500 |